key: cord-1019463-dpre835w
authors: Chen, Lingdan; Tang, Ruidi; Chen, Hongyuan; Huang, Yuhang; Yi, Shuting; Bai, Qianwen; Zhu, Yufan; Hong, Cheng; Liu, Chunli; Zhang, Nuofu; Wang, Tao
title: Pulmonary Vasculature: A Target for COVID-19
date: 2021-01-15
journal: Am J Respir Crit Care Med
DOI: 10.1164/rccm.202009-3564le
sha: 1ff5fcd07851b8920c179df2689a1ff1d27e58da
doc_id: 1019463
cord_uid: dpre835w

nan

ECMO maintains better cardiorespiratory interaction than venoarterial ECMO, and it does not increase LV end-diastolic pressure, left atrial pressure, and pulmonary venous pressure. A rise in mixed venous oxygen saturation diminishes hypoxic pulmonary vasoconstriction response to increase pulmonary vascular dilatation in diseased lobes. Furthermore, a higher minute ventilation because of hypoxic and hypercarbic drive may subside during ECMO, and the ventilatory ratio may also come down substantially. Admittedly, physiological dead space, shunt fraction, and ventilation perfusion matching would be entirely different in patients with acute hypoxemic failure on ECMO compared with patients not on ECMO. Furthermore, clinicians may be tempted to change the ventilator settings during ECMO run. Peripheral pulmonary vascular dilatation gets obscured by opacification of the lung, and the presence of such dilatation in a healthy aerated lung region suggests extraalveolar vessel dilatation as a result of intraalveolar vessel compression owing to positive end-expiratory pressure (5) . Demarcation of pulmonary vascular dilatation between precapillary and postcapillary component could have helped in assessing the role of pulmonary vascular resistance and LV dysfunction. Even though the sample size was small, stratification and comparison of oxygenation parameters and the computed tomographic scan findings in patients on ECMO and in patients not on ECMO would have provided an additional pathophysiological insight. In addition, comparisons among patients on different types of ECMO would have been worthwhile. The study did not provide sufficient data to suggest whether the correlation between different ventilatory and oxygenation parameters were assessed before ECMO or after ECMO. Furthermore, the author's interpretation that there was no correlation between the computed tomographic scan findings and Pa O 2 /FI O 2 ratio or the ventilatory ratio seems to suggest an overwhelming role of ECMO in improving Pa O 2 /FI O 2 ratio and ventilatory ratio in nearly 50% of patients. An increase or decrease in the incidence of pulmonary vessel dilatation, microthrombosis, and pulmonary thromboembolism during ECMO may indicate the qualitative and quantitative change required in anticoagulation therapy. A persistent increase in the incidence of pulmonary thromboembolism while on ECMO despite adequate activated clotting time could be worrying. In addition, establishing a correlation between change in prevalence of pulmonary vascular dilatation with increasing duration of ECMO run would also have been meaningful. To the Editor:

Coronavirus disease (COVID-19) is rapidly emerging and becoming a pandemic worldwide. The pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), infects the hosts via an ACE2 receptor, which is expressed in vascular endothelial cells. And SARS-CoV-2 has been found in blood vessels and causes a variety of vascular complications, including thrombosis (1). In a recent issue of the Journal, Patel and colleagues found a high rate of pulmonary embolism and distal pulmonary vascular dilation using computed tomography (CT) pulmonary angiography (CTPA) scans, and lung perfusion defects via dual-energy CT scans in patients with COVID-19 who were mechanically ventilated (2) . It is the first report of peripheral pulmonary vessel dilation presenting as a vascular tree-inbud pattern that was not reported in acute or chronic pulmonary embolism before. Interestingly, presence of peripheral pulmonary vessel dilation is associated with longer duration of hospitalization and ventilation. As SARS-CoV-2 infects blood vessels (1), the peripheral pulmonary vessel dilation could be caused by the virus infection or COVID-19-induced inflammation, which may be characteristic vascular damage in COVID-19 and associated with the severity of the disease. Lung pathology from patients with COVID-19 shows thrombus in the microvasculature (3), but whether these changes contribute to peripheral pulmonary vessel dilation in CTPA may need further investigation. In addition to lung CT examinations, thromboelastography was also performed on the patients in this study and showed hypercoagulability characterized by higher maximal amplitude and absent fibrinolysis at 30 minutes (lysis index 30 [LY30] = 0%). These thromboelastography findings may explain the reason why 38.5% of the patients had pulmonary embolisms even with anticoagulant prophylaxis, as the hypercoagulability state was mainly attributed to platelets and fibrin. Similarly, a recent study suggests that heparin treatment does not change mortality in severe COVID-19 cases (4) . In contrast, a case series study suggests that tissue plasminogen activator treatment improved COVID-19-associated acute respiratory distress syndrome (5) . Based on these findings, antiplatelet or fibrinolytic drugs could be studied for thrombosis prevention and treatment for patients with COVID-19 in the future.

However, this study raised several concerns. First, this study only included patients who underwent CTPA. The contrast medium used in CTPA may cause renal damage, which is also a common complication of COVID-19, and thus CTPA may not be routinely performed in patients with severe COVID-19 but only in those with suspected pulmonary embolism in the clinical practice. This may lead to a selection bias of patients and overestimate the rate of pulmonary embolism in patients with COVID-19 on mechanical ventilation, especially in such a retrospective study. Second, the average platelet counts were (272 6 77) 3 10 9 /L in the patients who received mechanical ventilation in this study, which were different from the previous cohort study in which thrombocytopenia has been reported to be common in patients who were critically ill with COVID-19 (6). Third, the therapy from pulmonary embolism was not discussed in this study; it would be interesting to discuss whether the treatment for pulmonary embolism in patients with COVID-19 should be different from pulmonary embolism treatment in patients without COVID-19.

Overall, Patel and colleagues' study (2) is interesting in demonstrating a high rate of peripheral pulmonary vessel dilation and pulmonary embolism in patients with COVID-19, which may suggest that pulmonary vasculature is a common target of COVID-19. How these vascular changes affect COVID-19 development may need further study. n Author disclosures are available with the text of this letter at www.atsjournals.org.

Pulmonary angiopathy in severe COVID-19: physiologic, imaging, and hematologic observations

Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19

Clinical pearls of venoarterial extracorporeal membrane oxygenation for cardiogenic shock

Hemodynamics of mechanical circulatory support

Positive end-expiratory pressure: when more may not be better

Endothelial cell infection and endotheliitis in COVID-19

Pulmonary angiopathy in severe COVID-19: physiologic, imaging, and hematologic observations

Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case series

Medical Treatment Expert Group for COVID-19. Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China

Reply to Sanfilippo et al. and to Caviedes et al.

We thank Sanfilippo and colleagues for their letter regarding the potential for convalescent plasma (CP) to promote macro-and microvascular thromboses in patients with coronavirus disease (COVID-19). CP is obtained through apheresis, at least 14 days following full recovery, from COVID-19 survivors who mount a satisfactory response with a high level of IgG antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (1). Implicit in this is that, at the time of collection, 1) the inflammatory response has subsided in potential donors and 2) levels of procoagulant (e.g., factor VIII, fibrinogen, von Willebrand factor, and inflammatory cytokines) and anticoagulant (including protein C, protein S, and antithrombin) proteins have normalized. In this way, the composition of CP simulates that of standard fresh frozen plasma (FFP), except for the presence of neutralizing antibodies against SARS-CoV-2. Both standard FFP and CP contain procoagulant and anticoagulant proteins, together with fibrinolytic activators such as plasminogen. One unit of CP